Why IMU is a multi multi bagger, page-23648

SquarePants, Did you read the following paragraph from the May Newsletter?


I can’t see how you could statement that IMU technology is no long worth the $50bb-$100bn you once would have thought possible.

And to address your comments that a Nasdaq listing is not likely to make much difference. Which you followed up with comments that you had pointed people towards IMU and they weren’t at all interested.

I did post today that the very reason we should be listed on the Nasdaq is because Aussie Funds and Investors are not interested in buying Biotechs. They don’t have the required skills to analyse them. They just don’t understand them at all. The US market has a deep pool of funds and experts capable of making good biotech investments.

IMU is the key that unlocks the access gateway to treating solid tumors. Many of those new treatments you refer to can use Oncarlytics to open the access to the $500bn market.

That was the main reason for the newsletter. To hammer that message home yi share holders.

Many of the posts here on HC highlight just how many holders don’t have a good grasp of what IMU actually does.

So it’s little wonder the SP struggles. As tacitly implied in the newsletter , this f successful IMU is well and truly worth $50-$100bn . We might even get our first news on Oncarlytics on the 2/6. And definitely getting data later in 2024.